Precigen (PGEN) shares are soaring in pre-market trading, jumping 5.39% as multiple analysts reaffirm their positive outlook on the company. The surge comes on the heels of maintained ratings and increased price targets from prominent financial institutions, signaling growing confidence in the biotech firm's prospects.

JMP Securities has maintained its Market Outperform rating on Precigen, while simultaneously raising its price target to $8 from $6. This represents a significant upside potential from the stock's current trading levels. Similarly, HC Wainwright & Co. has kept its price target for Precigen at $8.50 per share, further reinforcing the bullish sentiment surrounding the company.

The wave of positive analyst actions suggests that Wall Street is increasingly optimistic about Precigen's future. While specific details about the company's recent developments were not provided, the maintained ratings and increased price targets typically indicate that analysts see strong fundamentals and growth potential in the company. Investors appear to be responding favorably to these endorsements, as reflected in the stock's pre-market surge. As the trading day progresses, it will be interesting to see if Precigen can maintain this momentum and capitalize on the renewed analyst confidence.